Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.
Ontology highlight
ABSTRACT: Acting on the cytokine cascade is key to preventing disease progression and death in hospitalised patients with COVID-19. Among anti-cytokine therapies, interleukin (IL)-6 inhibitors have been the most used and studied since the beginning of the pandemic. Going through previous observational studies, subsequent randomised controlled trials, and meta-analyses, we focused on the baseline characteristics of the patients recruited, identifying the most favourable features in the light of positive or negative study outcomes; taking into account the biological significance and predictivity of IL-6 and other biomarkers according to specific thresholds, we ultimately attempted to delineate precise windows for therapeutic intervention. By stimulating scavenger macrophages and T-cell responsivity, I
SUBMITTER: Zizzo G
PROVIDER: S-EPMC8948465 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
ACCESS DATA